Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmidt, F.
Right arrow Articles by Weller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmidt, F.
Right arrow Articles by Weller, M.
Related Collections
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
NEUROLOGY 2006;66:587-589
© 2006 American Academy of Neurology
Brief Communications

PCV chemotherapy for recurrent glioblastoma

F. Schmidt, MD, J. Fischer, U. Herrlinger, MD, K. Dietz, MD, J. Dichgans, MD and M. Weller, MD

From the Department of General Neurology (F.S., J.F., U.H. J.D., M.W.), Hertie Institute for Clinical Brain Research and Department of Medicinal Biometry (K.D.), University of Tuebingen, Medical School, Tuebingen, Germany.

Address correspondence and reprint requests to Dr. Friederike Schmidt, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tuebingen, Medical School, Hoppe-Seyler-Strasse 3, D-72076 Tuebingen, Germany; e-mail: friederike.schmidt{at}uni-tuebingen.de

The authors administered procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, lomustine), and vincristine (PCV) to 86 patients with recurrent glioblastoma. There were three partial responses, but no complete responses. Median progression-free survival was 17.1 weeks and progression-free survival at 6 months was 38.4%. World Health Organization grade III/IV hematologic toxicity was common (25.6%), but nonhematologic toxicity was mild.

Disclosure: The authors report no conflicts of interest.

Received November 20, 2004. Accepted in final form October 28, 2005.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.